In a 46-patient first-in-human study of small- to medium-sized abdominal aortic aneurysms (AAA), Nectero’s investigational Nectero EAST System delivered a median aneurysm diameter growth of 1.00 mm per year over two years, with sites reporting 100% technical success and no major adverse events through 30 days and no treatment-related adverse events beyond 30 days. Preliminary analyses also indicated stability of the proximal neck at one year, with a full two-year neck analysis slated for release in June.
The company disclosed the two-year outcomes at Charing Cross 2026 and positioned the therapy— a single, local infusion of pentagalloylglucose (PGG) via a dual-balloon catheter— as an earlier intervention intended to slow aneurysm expansion and potentially defer or obviate the need for endograft or open repair. The procedure averaged under 45 minutes in this cohort, which had a median baseline diameter of 4.3 cm and typical AAA demographics. Nectero is now running a 400-patient randomized controlled trial comparing PGG treatment against standard surveillance to validate the signal on growth and neck behavior.
Strategically, this is a move to redefine AAA management upstream, where today’s standard is watchful waiting until size thresholds trigger EVAR or open surgery. Prior systemic pharmacology efforts have failed to deliver durable disease modification. By localizing therapy to the aneurysmal wall and avoiding a permanent implant, Nectero is testing a middle path: a device-enabled drug delivery aimed at the underlying matrix biology while preserving future repair options. The bet is that a measurable slowdown in expansion—paired with neck stabilization—can translate into delayed time-to-repair and lower rupture risk without adding longitudinal burden to patients or sites.
If the effect holds in randomized data, the implications are broad. Vascular surgery and interventional radiology centers could see a new outpatient procedural offering for a population historically managed with imaging surveillance alone. Operationally, the model is attractive: single visit, no implant, short procedure time. For sponsors and CROs, the pivotal study will be imaging-intensive and hinge on consistent ultrasound/CT measurements, central core lab adjudication, and site training to minimize variability—areas that often decide the credibility of growth-rate endpoints. For device makers, a credible disease-slowing therapy may reshuffle EVAR volumes and timing, but could also expand the eligible pool or improve neck anatomy when repair becomes necessary. Regulators will focus on moving from historical comparisons to prospective evidence that growth reduction and neck stability map to hard clinical outcomes such as rupture-free survival and time to intervention. Payers and guideline bodies will demand that translation before endorsing a new treatment paradigm for largely asymptomatic patients.
The next milestones will determine whether this signal matures into a new category. The late-breaking two-year neck data at VAM and the design details of the 400-patient RCT—primary endpoint selection, powering assumptions, imaging cadence, and event-driven components—will signal how aggressively Nectero is aiming for outcomes beyond diameter change. Enrollment pace is a watch item; convincing asymptomatic patients and clinicians to act earlier will test real-world acceptability. Three-year follow-up readouts by end-2026 should start to clarify durability. Execution risks include reproducibility of technical success across community and academic sites, maintaining low adverse event rates at scale, and navigating combination-product regulatory pathways. If the randomized trial links growth and neck effects to clinically meaningful delays in repair or rupture, the field could face a recalibration of surveillance-first strategies; if not, the signal may be relegated to a biomarker improvement without practice-changing force.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
